Alignment with the US Food and Drug Administration FDA on 50 mg twice daily as the recommended Phase 2 dose for Bh-30643 based on favorable PK, safety, and efficacy data to date Announced Solara-2, the single-arm pivotal
BLSM (BLSM) โ Live Session & Technical Brief
Updated Nov 22, 2026 7:31 AM ET ยท Prev Close $14.41
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (+0.69%) in Equities
Blsm (Blsm) is trading within a tight intraday band at $14.51 (+0.69%, 1.43x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, BLSM is outperforming the S&P 500 by +4.33%. 14-day RSI stands at 47.6, keeping momentum in a bearish regime.
Alignment with the US Food and Drug Administration FDA on 50 mg twice daily as the recommended Phase 2 dose for Bh-30643 based on favorable PK, safety, and efficacy data to date Announced Solara-2, the single-arm pivotal
Price ($14.51) trades relative to 20-day SMA ($14.33) and 50-day SMA ($17.27).
Market & Sector Relative Strength
BLSM outperforming the S&P 500 by +4.33%Recent BLSM Catalyst Headlines
Verified WireAlignment with the US Food and Drug Administration on 50 mg twice daily as the recommended Phase 2 dose for Bh-30643 Solara-2, the Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-3
Clinical data demonstrate target engagement and support the potential for Bh-30236 to address therapeutic resistance in relapsed refractory AML and Hr-Mdssan Diego, Nov. 04, 2026 Globe Newswire -- BlossomHill Therapeutic
San Diego, Nov. 03, 2026 Globe Newswire -- BlossomHill Therapeutics, Inc. Nasdaq BLSM , a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small
1โ3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $14.33 (20-day SMA support) for directional breakout confirmation.
Technical Regime (BLSM)
MIXED MA TRENDAbout BLSM
Get Instant BLSM Catalyst Alerts
Receive an email alert when BLSM triggers an unusual volume breakout, options sweep, or rating shift.
BLSM Session & Catalyst FAQ
Why is BLSM stock trading near flat today?
Blsm (Blsm) is trading within a tight intraday band at $14.51 (+0.69%, 1.43x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, BLSM is outperforming the S&P 500 by +4.33%. 14-day RSI stands at 47.6, keeping momentum in a bearish regime.
Is BLSM stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 1.43x relative volume (moderate participation). Our multi-factor model currently rates BLSM as AVOID NEW MONEY. Review full valuation, quality, and timing signals on the BLSM Buy or Sell Decision Brief โ
What is BLSM's intrinsic value and expected trading range?
At $14.51, BLSM's modeled 1-to-3 session range is $14.11 โ $14.91, with a key inflection level at $14.33 (20-day SMA support). Compare current price against multi-year cash flow projections in the BLSM Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for BLSM?
RSI at 47.6 reflects soft below-midline momentum. BLSM trades at $14.51 relative to its 20-day SMA ($14.33) and 50-day SMA ($17.27), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.